![Barbara Chan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Barbara Y.
Chan is currently working as the CFO, CAO & Senior Vice President-Finance at Omega Therapeutics, Inc. She previously worked as the President & Director at Aegerion Pharmaceuticals, Inc. and as the Chief Accounting Officer at Novelion Therapeutics, Inc. Ms. Chan completed her undergraduate and graduate degrees at Bentley University.
Postes actifs de Barbara Chan
| Sociétés | Poste | Début |
|---|---|---|
| OMEA THER | Directeur Financier/CFO | 31/05/2024 |
Anciens postes connus de Barbara Chan
| Sociétés | Poste | Fin |
|---|---|---|
| NOVELION THERAPEUTICS INC. | Comptroller/Controller/Auditor | 24/09/2019 |
| AEGERION PHARMACEUTICALS, INC. | President | - |
Formation de Barbara Chan
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Aegerion Pharmaceuticals, Inc.
 Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and commercializes therapies for hyperlipidemia and metabolic diseases | Health Technology |
Bentley University
 Bentley University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novelion Therapeutics, Inc.
 Novelion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets rare disease products, metreleptin and lomitapide | Health Technology |
Omega Therapeutics, Inc.
 Omega Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics for general and rare genetic diseases, immunology, inflammation, oncology and metabolic diseases | Health Technology |
Choisissez Zonebourse 
